+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Qiagen NV (QIA) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 66 Pages
  • April 2023
  • GlobalData
  • Qiagen N.V.
  • ID: 1290784
Qiagen NV (QIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company’s sample technologies help isolate and process DNA, RNA, and proteins from samples such as blood, tissue and other materials; assay technologies to identify the genetic information of a pathogen in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers products directly and also through a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.

Qiagen NV Key Recent Developments

  • Apr 20, 2023: QIAGEN announces expansion of supervisory board
  • Mar 10, 2023: Qiagen partners with Servier to develop new test for AML drug
  • Mar 01, 2023: QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
  • Feb 07, 2023: QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Qiagen NV - Key Facts
  • Qiagen NV - Key Employees
  • Qiagen NV - Key Employee Biographies
  • Qiagen NV - Major Products and Services
  • Qiagen NV - History
  • Qiagen NV - Company Statement
  • Qiagen NV - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Qiagen NV - Business Description
  • Product Category: Consumables and Related Revenues
  • Overview
  • Performance
  • Product Category: Instrumentation
  • Overview
  • Performance
  • Geographical Segment: Asia Pacific, Japan and Rest of World
  • Performance
  • Geographical Segment: Europe, Middle East and Africa
  • Performance
  • Geographical Segment: Other Americas
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Qiagen NV - Corporate Strategy
  • Qiagen NV - SWOT Analysis
  • SWOT Analysis - Overview
  • Qiagen NV - Strengths
  • Qiagen NV - Weaknesses
  • Qiagen NV - Opportunities
  • Qiagen NV - Threats
  • Qiagen NV - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Qiagen NV, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Qiagen NV, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Qiagen NV, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 20, 2023: QIAGEN announces expansion of supervisory board
  • Mar 10, 2023: Qiagen partners with Servier to develop new test for AML drug
  • Mar 01, 2023: QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
  • Feb 07, 2023: QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
  • Feb 01, 2023: GTG to form strategic alliance with global testing leader QIAGEN
  • Nov 14, 2022: PHI, SAS, QIAGEN and BioSpherix form Alliance to Advance Cell-based Biomanufacturing
  • Nov 14, 2022: PHI, SAS, QIAGEN and BioSpherix form alliance to advance cell-based biomanufacturing
  • Sep 15, 2022: Qiagen and Neuron23 partner to develop CDx for Parkinson’s disease drug
  • Aug 18, 2022: QIAGEN issues 2021 Sustainability Report
  • Aug 15, 2022: Qiagen introduces QIAstat-Dx Viral Vesicular Panel RUO for monkeypox
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Qiagen NV, Key Facts
  • Qiagen NV, Key Employees
  • Qiagen NV, Key Employee Biographies
  • Qiagen NV, Major Products and Services
  • Qiagen NV, History
  • Qiagen NV, Subsidiaries
  • Qiagen NV, Joint Venture
  • Qiagen NV, Key Competitors
  • Qiagen NV, Ratios based on current share price
  • Qiagen NV, Annual Ratios
  • Qiagen NV, Interim Ratios
  • Qiagen NV, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Qiagen NV, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Qiagen NV, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Qiagen NV, Performance Chart (2018 - 2022)
  • Qiagen NV, Ratio Charts
  • Qiagen NV, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Qiagen NV, Medical Equipment, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • MilliporeSigma
  • Hologic Inc
  • Promega Corp
  • 4basebio AG
  • Roche Diagnostics International Ltd